CD309 (FLK1) Monoclonal Antibody (Avas12a1), Super Bright™ 436, eBioscience™, Invitrogen™

Beschreibung

Description: The Avas12a1 monoclonal antibody reacts with mouse Flk-1, also known as vascular endothelial growth factor receptor 2 (VEGFR2). Flk-1 is a receptor tyrosine kinase involved in vascular endothelial tissue development and is expressed on endothelial cells during embryonic stages and some endothelial tissues in the adult. Applications Reported: This Avas12a1 antibody has been reported for use in flow cytometric analysis. Applications Tested: This Avas12a1 antibody has been tested by flow cytometric analysis of bEnd.3 cells. This may be used at less than or equal to 1.0 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm. We recommend using a 450/50 bandpass filter, or equivalent. Please make sure that your instrument is capable of detecting this fluorochrome. When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Staining Buffer (Product No. SB-4400) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information.

KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase. It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors. FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.